Wockhardt Limited , a leading pharmaceutical and biotechnology company, has reported a robust performance for the second quarter, with its domestic biotech business emerging as a key growth driver.

Profit Turnaround and Revenue Growth

The company has shown a significant turnaround in its financial performance, reporting a profit before tax of Rs. 91.00 crore for Q2, compared to a loss of Rs. 109.00 crore in the previous quarter. This marks a substantial improvement in the company's profitability.

Wockhardt's revenue for Q2 stood at Rs. 782.00 crore, up from Rs. 738.00 crore in the previous quarter, representing a quarter-on-quarter growth of 6%. The company's EBITDA also saw a remarkable 58% quarter-on-quarter growth, reaching Rs. 160.00 crore in Q2 compared to Rs. 101.00 crore in the earlier quarter.

Biotech Business: A Star Performer

The domestic biotech operations have emerged as a standout performer for Wockhardt. The segment recorded an impressive growth of 42% compared to Q4 and 41% versus Q1, with overall biotech operations for the quarter standing at Rs. 154.00 crore.

Wockhardt's management expects this business segment to continue thriving in the future, driven by accelerated business opportunities and strategic partnerships in key markets such as Thailand, Egypt, Algeria, and Latin America.

Geographical Performance

The company's performance across different geographies showed mixed results:

The Irish business, in particular, demonstrated strong growth, while the Indian and UK markets showed modest improvements.

Novel Antibiotics and Product Pipeline

Wockhardt continues to make strides in its novel antibiotics portfolio:

1. ZAYNICH®: The company submitted a New Drug Application (NDA) to the U.S. FDA for its novel antibacterial agent WCK 5222.
2. MIQNAF® (Nafithromycin): Approved and launched in India, with its Phase 3 study published in the prestigious LANCET journal.
3. EMROK/EMROK O: Included in Clinical Infectious Disease Society's official diagnosis and treatment guidelines.

Future Outlook

With its strong performance in the biotech segment and a robust pipeline of novel antibiotics, Wockhardt appears well-positioned for future growth. The company's focus on strategic partnerships and expansion into new markets, particularly in the biotech and diabetes care segments, suggests a positive outlook for the coming quarters.

As Wockhardt continues to leverage its integrated biotech infrastructure and advance its leadership in diabetes care, investors and industry observers will be keenly watching the company's progress in translating these opportunities into sustained financial growth.

Wockhardt Limited , a prominent player in the Indian pharmaceutical sector, has reported a turnaround in its financial performance for the second quarter of fiscal year 2026. The company posted a profit after tax of Rs. 82.00 crore for Q2FY26, compared to a loss of Rs. 109.00 crore in the previous quarter.

Financial Highlights

• Revenue from operations stood at Rs. 782.00 crore in Q2FY26, up from Rs. 738.00 crore in Q1FY26.
• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a significant 58% quarter-on-quarter growth, reaching Rs. 160.00 crore in Q2FY26 compared to Rs. 101.00 crore in the previous quarter.
• The company reported a profit before tax of Rs. 91.00 crore for Q2FY26, a substantial improvement from the loss of Rs. 109.00 crore in Q1FY26.

Exit from US Generic Pharmaceutical Business

In a strategic move, Wockhardt has decided to exit the US generic pharmaceutical business. The company filed for voluntary liquidation on July 11, 2025, under Chapter 7 of the US Bankruptcy Code for its US step-down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. This decision resulted in an exceptional item charge of Rs. 97.00 crore in the financial results for the period ended September 30, 2025.

Business Performance

• The India Business reported a revenue of Rs. 172.00 crore in Q2FY26, showing a 3% growth compared to the previous year.
• UK Business revenue stood at Rs. 313.00 crore, with a 4% year-on-year growth.
• Irish Business saw significant growth, with revenue reaching Rs. 59.00 crore, a 40% increase compared to the previous year.

Novel Antibiotics Progress

Wockhardt continues to make strides in its novel antibiotics portfolio:

1. ZAYNICH®: The company submitted a New Drug Application (NDA) to the U.S. FDA in September 2025 for its novel antibacterial agent WCK 5222, ZAYNICH.

2. MIQNAF® (Nafithromycin): Approved and launched in India on May 27, 2025. The Phase 3 CABP study was published in the prestigious LANCET journal.

3. EMROK/EMROK O: Included in Clinical Infectious Disease Society's official diagnosis and treatment guidelines for 2025.

Biotech Operations

The Biotech segment showed robust growth, with overall operations for the quarter standing at Rs. 154.00 crore, recording a growth of 42% compared to Q4 FY25 and 41% versus Q1 FY26.

Intellectual Property

Wockhardt continues to strengthen its intellectual property portfolio:

• 7 patents were filed during the quarter ended September 30, 2025.
• The company was granted 5 patents during the quarter and now holds a total of 858 patents.

Wockhardt's Chairman, Dr. Habil Khorakiwala, stated, "Our focus on novel antibiotics and strategic decisions are beginning to show positive results. The exit from the US generic business allows us to concentrate on high-growth areas and innovative products."

As Wockhardt continues to navigate the challenging pharmaceutical landscape, investors and industry observers will be keenly watching its progress in novel antibiotics and the impact of its strategic decisions on future growth.